1. Scrip

Vericel Jumps On Positive Heart Failure Data

 
• By Lisa LaMotta

Vericel more than doubled its stock price on March 10 after results from a mid-stage heart failure study showed its regenerative medicine helped improve seriously ill patients.

The Cambridge, Mass.-based biotech said results of the Phase IIb ixCELL-DCM study of ixmyelocel-T in patients with advanced heart failure...

More from Cardiovascular

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.